Literature DB >> 14504808

[Special features of intensive care of toxic shock syndrome. Review and case report of a TSST-1 associated toxic-shock syndrome with adult respiratory distress syndrome and multiple organ failure from a staphylococcal panaritium].

C Lang1, H Behnke, J Bittersohl, L Eberhart, E Walthers, F Sommer, H Wulf, G Geldner.   

Abstract

Toxic-shock-syndrome (TSS) is an acute febrile, exanthematous illness caused by toxins such as toxic-shock-syndrome-toxine-1 (TSST-1) and other endotoxines from staphylococcus aureus with an incidence of 0,5 per 100.000 inhabitants. Patients with menstrual toxic-shock-syndrome (menstrual-TSS) usually have TSS associated with menstruation and use of a vaginal device such as tampons. Other patients with non-menstrual toxic-shock-syndrome (non-menstrual-TSS) have a focus of staphylococcal infection such as a surgical wound infection or soft tissue abscess. TSS usually presents with fever, pharyngitis, diarrhoea, vomiting, myalgia and may progress rapidly (within hours) to signs of hypovolaemic hypotension and shock. In some cases TSS is associated with multisystem failure including shock, renal failure, myocardial failure and adult respiratory distress syndrome. In its acute phase the diagnosis of TSS is often uncertain because of its initial symptoms are non-specific and numerous conditions need to be considered in the differential diagnosis. But obviously less incidence, the signs and symptoms of toxic-shock-syndrome should be recognised early to permit successful therapy. The site of infection should be adequately drained and treated with antimicrobial therapy. Possible complications including ARDS and myocardial failure require a thorough understanding of its underlying pathophysiology to ensure appropriate intensive-care treatment. Only if appropriate therapy is instituted as early as possible, most of patients will be able to survive their toxic-shock-syndrome. In other cases TSS can be a rapidly progressive and perhaps lethal ending disease because of possible multiple organe failure such as ARDS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504808     DOI: 10.1007/s00101-003-0552-5

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  17 in total

1.  [Experience with extracorporeal CO2 elimination].

Authors:  M Knoch; E E Müller; W Höltermann; H Konder; H Lennartz
Journal:  Anaesthesist       Date:  1987-05       Impact factor: 1.041

2.  Toxin involvement in toxic shock syndrome.

Authors:  B A Crass; M S Bergdoll
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

3.  Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses.

Authors:  K C Kain; M Schulzer; A W Chow
Journal:  Clin Infect Dis       Date:  1993-01       Impact factor: 9.079

4.  [Toxic shock syndrome. Pathogenesis, diagnosis, therapy].

Authors:  R Hirschberg; K Schaefer
Journal:  Dtsch Med Wochenschr       Date:  1983-06-10       Impact factor: 0.628

5.  An alternative to breathing.

Authors:  T Kolobow; L Gattinoni; T Tomlinson; J E Pierce
Journal:  J Thorac Cardiovasc Surg       Date:  1978-02       Impact factor: 5.209

6.  Acute respiratory distress in adults.

Authors:  D G Ashbaugh; D B Bigelow; T L Petty; B E Levine
Journal:  Lancet       Date:  1967-08-12       Impact factor: 79.321

7.  Destructive pulmonary embolism in a patient with community-acquired staphylococcal bacteremia.

Authors:  Taku Miyashita; Yuko Shimamoto; Hajime Nishiya; Yoji Koshibu; Hajime Sugiyama; Yasuo Ono; Takayoshi Satoh; Hitomi Haraoka; Junichi Nakano; Ken Ohta; Tomohide Sato; Naoko Morinaga; Masatoshi Noda
Journal:  J Infect Chemother       Date:  2002-03       Impact factor: 2.211

8.  Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases.

Authors:  S M Larkin; D N Williams; M T Osterholm; R W Tofte; Z Posalaky
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

9.  Treatment of acute respiratory failure with low-frequency positive-pressure ventilation and extracorporeal removal of CO2.

Authors:  L Gattinoni; A Agostoni; A Pesenti; A Pelizzola; G P Rossi; M Langer; S Vesconi; L Uziel; U Fox; F Longoni; T Kolobow; G Damia
Journal:  Lancet       Date:  1980-08-09       Impact factor: 79.321

10.  Staphylococcus aureus associated with toxic shock syndrome: phage typing and toxin capability testing.

Authors:  W A Altemeier; S A Lewis; P M Schlievert; M S Bergdoll; H S Bjornson; J L Staneck; B A Crass
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

View more
  5 in total

1.  [Toxic shock syndrome after open ankle fracture].

Authors:  T Klüter; S Fitschen-Oestern; M Weuster; H Fickenscher; A Seekamp; S Lippross
Journal:  Unfallchirurg       Date:  2015-07       Impact factor: 1.000

2.  [Toxic shock syndrome (TSS) after a postsurgery knee infection].

Authors:  M de Jesus Pereira; K Jäckle
Journal:  Orthopade       Date:  2010-11       Impact factor: 1.087

3.  Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated with Coronavirus Disease-2019.

Authors:  Prakash Nagarkatti; Kathryn Miranda; Mitzi Nagarkatti
Journal:  Front Pharmacol       Date:  2020-11-06       Impact factor: 5.810

4.  [Toxic shock syndrome due to Staphylococcus aureus in a small child, a (clinical or laboratory chemical) visual diagnosis?]

Authors:  C Konietzka; M Schneider-Kruse; D Knaack; C Krüger; F Layer; M Endmann
Journal:  Monatsschr Kinderheilkd       Date:  2020-11-30       Impact factor: 0.416

5.  Endocannabinoid Anandamide Attenuates Acute Respiratory Distress Syndrome through Modulation of Microbiome in the Gut-Lung Axis.

Authors:  Muthanna Sultan; Kiesha Wilson; Osama A Abdulla; Philip Brandon Busbee; Alina Hall; Taylor Carter; Narendra Singh; Saurabh Chatterjee; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.